China Universal Asset Management Co. Ltd. Has $458,000 Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

China Universal Asset Management Co. Ltd. boosted its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 64.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,285 shares of the company’s stock after purchasing an additional 5,582 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in SpringWorks Therapeutics were worth $458,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after purchasing an additional 474 shares during the last quarter. Creative Planning bought a new position in SpringWorks Therapeutics in the 3rd quarter valued at approximately $254,000. Handelsbanken Fonder AB boosted its position in SpringWorks Therapeutics by 18.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 23,400 shares of the company’s stock worth $750,000 after buying an additional 3,600 shares during the period. Quarry LP grew its holdings in SpringWorks Therapeutics by 56.3% during the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,800 shares during the last quarter. Finally, Algert Global LLC increased its position in SpringWorks Therapeutics by 62.7% in the 2nd quarter. Algert Global LLC now owns 34,989 shares of the company’s stock valued at $1,318,000 after acquiring an additional 13,489 shares during the period.

Wall Street Analysts Forecast Growth

SWTX has been the topic of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. JPMorgan Chase & Co. upped their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, HC Wainwright restated a “buy” rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of “Buy” and an average target price of $68.50.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX opened at $30.48 on Thursday. The company has a market capitalization of $2.26 billion, a P/E ratio of -5.93 and a beta of 0.78. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $53.92. The company’s 50 day moving average price is $34.58 and its 200-day moving average price is $37.97.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to analyst estimates of $34.42 million. The firm’s revenue for the quarter was up 59732900.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.25) EPS. Analysts forecast that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.